Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2016

View Archived Issues

Cobitolimod approved as the international nonproprietary name for Kappaproct

Shanghai Haiyan Pharmaceutical and Yangtze River Pharmaceutical Group report EGFR inhibitors

Atlantic Healthcare initiates phase III trial of alicaforsen to treat IBD pouchitis

FDA grants Novartis' dabrafenib orphan drug designation for malignant glioma

Regeneron's evinacumab granted U.S. orphan status for homozygous familial hypercholesterolemia

siRNA ALN-GO1 given FDA orphan designation for treating primary hyperoxaluria type 1

Shire reports key developments of fourth quarter 2015

Unique mechanism uncovered for high-risk leukemia

Filaggrin inhibits formation of lipid antigens in human skin

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

FDA issues complete response letter for Remune BLA

Boehringer Ingelheim Pharma patents DPP-I inhibitors

Ferrer discloses antibacterial agents

Roche patent describes TaR-1 ligands

Merck & Co. reports development of CETP inhibitors

Zealand initiates phase II trial of ZP-1848 for short bowel syndrome

Janssen Pharmaceutica divulges mGlu2 receptor modulators

e-Therapeutics reports topline phase IIb results for ETS-6103 in major depressive disorder

JHL Biotech cleared to begin phase I study of rituximab biosimilar JHL-1101

Discovery of a novel RNA delivery system to treat B-cell malignancies

M3 Biotechnology completes series A financing, to move lead compound into clinic

Ennaid Therapeutics to develop therapy for Zika virus

XBiotech enters agreement regarding antibodies for cardiovascular diseases

Achillion Pharmaceuticals begins clinical study of complement factor D inhibitor

FDA awards orphan drug designation to NVX-508 for VOC and ACS in sickle cell disease

Regeneron Pharmaceuticals joins Human Vaccines Project

Incyte to discontinue solid tumor studies of ruxolitinib

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...